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Abstract
Background: The binding between peptide epitopes and major histocompatibility complex
proteins (MHCs) is an important event in the cellular immune response. Accurate prediction of the
binding between short peptides and the MHC molecules has long been a principal challenge for
immunoinformatics. Recently, the modeling of MHC-peptide binding has come to emphasize
quantitative predictions: instead of categorizing peptides as "binders" or "non-binders" or as "strong
binders" and "weak binders", recent methods seek to make predictions about precise binding
affinities.
Results: We developed a quantitative support vector machine regression (SVR) approach, called
SVRMHC, to model peptide-MHC binding affinities. As a non-linear method, SVRMHC was able to
generate models that out-performed existing linear models, such as the "additive method". By
adopting a new "11-factor encoding" scheme, SVRMHC takes into account similarities in the
physicochemical properties of the amino acids constituting the input peptides. When applied to
MHC-peptide binding data for three mouse class I MHC alleles, the SVRMHC models produced
more accurate predictions than those produced previously. Furthermore, comparisons based on
Receiver Operating Characteristic (ROC) analysis indicated that SVRMHC was able to out-
perform several prominent methods in identifying strongly binding peptides.
Conclusion: As a method with demonstrated performance in the quantitative modeling of MHC-
peptide binding and in identifying strong binders, SVRMHC is a promising immunoinformatics tool
with not inconsiderable future potential.
Background
The T cell, a specialized type of immune cell, continuously
searches out proteins originating from pathogenic organ-
isms, such as viruses, bacteria, fungi, or parasites. The T
cell surface is enriched in a particular receptor protein: the
T cell receptor or TCR, which binds to major histocompat-
ibility complex proteins (MHCs) expressed on the sur-
faces of other cells. MHCs bind small peptide fragments
derived from both host and pathogen proteins. It is the
recognition of such complexes that lies at the heart of the
cellular immune response. These short peptides are
known as epitopes. Although the significance of non-pep-
tide epitopes, such as lipids and carbohydrates, is now
understood increasingly well, peptidic B cell and T cell
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immune systems respectively) remain the primary tools
by which the intricate complexity of the immune response
might be examined. While the prediction of B-cell
epitopes remains primitive [1], a multiplicity of sophisti-
cated methods for the prediction of T-cell epitopes has
developed [2].
The earliest efforts in predicting the binding of short pep-
tides to MHC molecules focused on identifying peptide
sequence motifs that were characteristic of binding to
MHC [3]. This motif approach assumed that the presence of
certain residues at specific positions (which are referred to
as "anchor" positions) critically defined the binding abil-
ity of the peptide to the MHC. This somewhat simplistic
assumption rendered the motif approach prone to false pre-
dictions. Later methods adopted more informative repre-
sentations of peptide binding and more sophisticated
modeling strategies such as position-specific scoring
matrices (PSSM) [4-7], artificial neural networks (ANN)
[8-10], hidden Markov model (HMM) [11] and support
vector machine (SVM) classification [12,13]. With
increasing amounts of MHC-peptide binding data availa-
ble to facilitate their optimization, these methods have
become increasingly effective in making predictions
about whether a given peptide binds to a particular MHC
molecule, and – when it does bind – whether the binding
is strong or weak.
Recently, the modeling of MHC-peptide binding has
come to emphasize quantitative predictions: instead of
categorizing peptides as "binders" or "non-binders" or as
"strong binders" and "weak binders", several new meth-
ods make predictions about the precise binding affinities
(usually expressed as pIC50, the negative logarithm of the
IC50). The additive method developed by Doytchinova et al.
is a representative example of this trend. In this method,
the binding affinity of the MHC-peptide interaction is
modeled as the sum of peptide background contribution
(a constant term), the amino acid contributions at each
position, and (optionally) the adjacent peptide side-chain
interaction [14]. The additive method has been shown to
be effective in modeling MHC-peptide binding for a range
of human and mouse class I MHC molecules, and, using
an iterative extension, also a set of human and mouse
Class II alleles [14-17]. Additive method models not only
provide more precise information about the binding reac-
tions, but also demonstrated enhanced accuracy in the
prediction of untested peptides compared to other predic-
tion methods such as SYFPEITHI, BIMAS and RANKPEP
[16,17].
In this paper, we shall explore how potential improve-
ments might be made in quantitative immunoinformatic
techniques, such as the additive method. First, utilizing
non-linearity, since properly chosen non-linear models
can, in describing complex systems, often out-perform
linear models. Second, the use of a more informative
scheme for encoding amino acids since most immunoin-
formatic methods encode amino acids by their identities
using indicator variables, information concerning similar-
ities in physicochemical properties between the 20 amino
acids is typically neglected.
Support Vector Machines (SVMs) are a class of learning
based non-linear modeling techniques with proven per-
formance in a wide range of practical applications [18].
Originally, SVMs were developed for classification or
qualitative modeling problems. With the introduction of
an ε-insensitive loss function, SVMs have been extended
to solve nonlinear regression (or quantitative modeling)
problems. In this study, we employed the SVM regression
(SVR) technique to model MHC-peptide binding affini-
ties for three mouse class I MHC alleles (H2-Db, H2-Kb
and H2-Kk). We name this new modeling method
SVRMHC. In SVRMHC models, peptides were described
using a new 11-factor encoding scheme. This takes into
account a number of important physicochemical parame-
ters of the 20 amino acids (including hydrophobicity
scale, polarity, isoelectric point, and accessible surface
area). These SVRMHC models demonstrated consistently
better performance than linear methods in terms of
describing power, self-consistency, and prediction accu-
racy. Moreover, comparisons between our SVR models
and several other popular prediction tools indicated that
the SVRMHC models performed best in identifying strong
binders to mouse class I MHC molecules.
The datasets used in this study, and the online implemen-
tation of the SVRMHC models for the three mouse class I
alleles, can be accessed on the supplementary web site
[19].
Results
SVR model parameter optimization
For the training of the SVR models, one kernel parameter
(γ), and two kernel-independent parameters (ε and C)
need to be determined (Eq.(5)). There are no commonly
agreed methods for determining optimal SVR model
parameters. In most published SVR studies we have exam-
ined, these model parameters were determined one at a
time, by first fixing all other parameters, then letting the
parameter take a range of different values, and thus iden-
tifying the value that corresponds to the best model per-
formance assessed by cross-validation [20,21]. This
method, though efficient in terms of execution time, dis-
regards potential interactions between different model
parameters. Cherkassky and Ma [22] advocated picking
two of the three SVR model parameters (ε and C) from
training data based on characterizations of the data, suchPage 2 of 13
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theoretically sound, did not, in our hands, always find the
best set of parameters. In this study, we adopted a param-
eter selection procedure that combines the method of
Cherkassky and Ma's with a grid-search. For ε and C, we
first calculated the "recommended value" using Cher-
kassky and Ma's formulas, then searched a parameter
range from 1/10th of the recommended value to 10 times
the recommended value. The kernel parameterγ does not
depend on the datasets. We picked a search range for γ as
[0.001, 1], which safely covered the γ ranges commonly
used in the literature [20,21,23]. After setting search
ranges for the three parameters, we undertook a grid-
search through the three-dimensional parameter space.
For each parameter, four, six or eight equal-sized steps (on
logarithm scale) were taken in the grid-search.
The H2-Kk dataset includes a large number of peptides
(154 octamers), and five-fold cross-validation was per-
formed to find the optimal parameters for the H2-Kk
model (Figure 1). The other two datasets – H2-Db and
H2-Kb – contain fewer peptides (65 nonamers and 62
octamers, respectively), thus a finer grained (and compu-
tationally more expensive) LOO cross-validation was
used to search for optimal parameters for the models of
these two MHC molecules. This LOO cross-validation is
part of the model parameter search, and it should not be
confused with the LOO cross-validation used in assessing
the model performance (see Methods). The combination
of the three parameters, γ, ε and C that leads to the small-
est root mean square (RMS) error was taken as the optimal
parameter combination. The RMS error is calculated as the
following:
A schematic diagram of the five-fold cross-validation scheme for the training and testing of the SVRMHC model constructed for H2-Kk (154 peptides), with enclosing parameter searching modules  which leave-one-out (LOO) cross-va idation was usedFigur  1
A schematic diagram of the five-fold cross-validation scheme for the training and testing of the SVRMHC model constructed 
for H2-Kk (154 peptides), with enclosing parameter searching modules in which leave-one-out (LOO) cross-validation was 
used. The models for the other two datasets (for H2-Db and H2-Kb) were constructed similarly, with the exception that the 
computationally more expensive LOO cross-validation (rather than five-fold cross-validation) was used on the outer-loop 
model training and testing procedure.Page 3 of 13
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and  are the predicted and experimentally meas-
ured pIC50 values for the ith peptide, respectively. The
final model parameters for the three MHC molecules were
determined via voting among the set of optimal parame-
ters during cross-validated model training. These parame-
ters are presented in Table 1.
SVRMHC models performed better than linear models in 
quantitative predictions
The SVRMHC models constructed for the three MHC mol-
ecules demonstrated consistently better performance than
linear models built from the same datasets.
The H2-Db dataset consisted of 65 nonamer peptides and
associated binding affinities. We compared the SVRMHC
method to the additive model, taken as typical of linear
methods, as shown in Table 2. Following a step-wise out-
lier exclusion procedure, the SVRMHC method deter-
mined and removed 3 outliers at a 2.0 log unit residual
cut-off (see Methods), while the additive method removed
6. The smaller number of outliers determined by the
SVRMHC method suggests that this method has more
"descriptive power" than the additive method. The self-
testing model constructed using the SVRMHC method
resulted in an r2 of 0.749 when the entire dataset was con-
sidered (including outliers), and an r2 of 0.983 was
obtained after the outliers were removed, compared to
additive model r2 values of 0.602 and 0.946, respectively.
The AR values of the SVRMHC model with and without
outliers were 0.170 and 0.043 respectively, smaller than
the corresponding additive AR values of 0.403 and 0.187.
The most interesting performance metric is perhaps the
LOO cross-validated q2, as it is more indicative of predic-
tion performance when tested on unseen data. q2 for the
SVRMHC method was 0.456. This is higher than the addi-
tive LOO cross-validated q2 value of 0.401.
The H2-Kb dataset consisted of 62 octamer peptides and
associated binding affinities (Table 2). With SVRMHC, the
step-wise outlier exclusion procedure determined and
excluded 6 outliers, compared to 7 outliers removed by
the additive method. The self-testing model constructed
using the SVRMHC method produced an r2 of 0.568 for
the entire dataset (including outliers), in contrast to the r2
of 0.370 produced by the additive model. An r2 of 0.970
was obtained with SVRMHC after the 6 outliers were
excluded, which was lower than the r2 obtained by the
additive model (0.989) after the exclusion of 7 outliers.
The AR of the SVRMHC model for the entire dataset
(including outliers) was 0.382 and the AR of the additive
method was 0.443. However, the AR of the SVM model
after the 6 outliers were removed (0.130) was higher than
the AR of the additive model after 7 outliers were removed
(0.095). The LOO cross-validated q2 of the model con-
structed with SVRMHC was 0.486, slightly higher than the
additive LOO cross-validated q2 of 0.454. These results
indicated that for the H2-Kb dataset, SVRMHC produced
models that had higher descriptive power and prediction
accuracy, though the self-testing model exhibited lower
level of self-consistency after the outliers were removed.
The H2-Kk dataset is the largest of the three datasets, con-
sisting of 154 octamers and associated binding affinities.
No outliers were excluded compared to 2 outliers using
the additive method. This, again, suggests that the
SVRMHC method has higher "descriptive power" than
linear methods. The self-testing additive model produced
an r2 of 0.849 (whole dataset) and 0.933 (2 outliers
excluded). The self-testing SVRMHC model gave an r2 of
0.973. Since no outlier was determined, there is only one
r2 calculated. The AR for the SVRHMC model was 0.039,
compared to the additive model, which gave 0.178 for the
entire dataset and 0.151 after the outliers were removed.
The LOO cross-validated q2 for SVRMHC was 0.721, com-
pared to an additive LOO cross-validated q2 of 0.456.
SVRMHC models out-performed other methods in 
identifying strong binders
We compared the performance of SVRMHC to that of
existing prediction tools for MHC-peptide binding: the
additive method, SYFPEITHI [5], BIMAS [6], RANKPEP
[7], and SVMHC [12]. At first, we attempted a strategy
described in [16,17]: trying to find recent literature reports
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Table 1: The parameters recommended by Cherkassky and Ma (2004) (ε and C) and the final optimized parameters (ε, C and γ) of the 
SVRMHC models constructed for the three mouse class I alleles.
ε-recommended ε-optimized C-recommended C-optimized γ-optimized
Model for H2-Db 0.0475 0.0150 10.34 18.39 0.0316
Model for H2-Kb 0.0513 0.5134 10.88 34.41 0.0316
Model for H2-Kk 0.0152 0.0152 10.00 10.00 0.3162Page 4 of 13
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class I MHC molecules. The hope was that predictions
could be made for these binding experiments using both
the SVRMHC model and the other methods, and a con-
comitant comparison in prediction accuracy could be
made. However, this strategy was not successful, because
in most recently-published binding experiments pre-
screening with prediction tools was used. This was most
often SYFPEITHI and sometimes BIMAS [24-29]. Only the
peptides predicted to be strong binders were tested exper-
imentally, and peptides not predicted to be strong binders
were disregarded. Moreover, false predictions (peptides
predicted by SYFPEITHI or BIMAS to be strong binders but
which were determined experimentally to be weak bind-
ers or non-binders) were sometimes not reported
[24,26,27]. It is not surprising that prediction tools used
in pre-screening (SYFPEITHI or BIMAS) always performed
better in identifying good binders in these published stud-
ies (results not shown).
Thus, we applied another scheme for making compari-
sons between the SVRMHC method and other prediction
methods – by using Receiver Operating Characteristic
(ROC) analysis [30,31]. The prediction performance of
any classification-type model can be assessed using the
combination of two properties – specificity and sensitiv-
ity. The sensitivity vs. (1-specificity) relationship is referred
to as the ROC relationship (see Methods). In a ROC curve,
the two axes both have a range of [0, 1], therefore the area
under a ROC curve (AROC) also takes a range of [0, 1]. A
purely "random guess" prediction model would have an
AROC of 0.5. For better models, AROC would be higher than
0.5. The closer AROC is to 1, the better the performance is
for the predicting model.
In the MHC ligand database MHCBN [32], we down-
loaded all nomamer ligands for the H2-Db molecule and
all octamer ligands for H2-Kb and H2-Kk. These peptides
were grouped into two groups: "strong binders" and
"weak binders" (see Methods). For H2-Db, there were 28
strong binders and 44 weak binders, and for H2-Kb, there
were 22 strong binders and 24 weak binders. No weak
binders were retrieved for the H2-Kk, thus no ROC analy-
sis was conducted for this allele. The scores generated by
these different prediction methods have very different
meanings. The scores produced by the SVRMHC models
and the additive models are predicted pIC50 values, while
scores from BIMAS are predicted half lives. RANKPEP out-
puts scores calculated from a PSSM (position-specific
score matrix) profile. The scores produced by SYFPEITHI
are nominal scores. They are generated by differentially
scoring matches, within an individual peptide, to primary
and secondary anchors within the target motif. Thus, they
represent how close a particular peptide is to the expected
pattern of a motif. The scores produced by SVMHC, on the
other hand, are the distances between the peptides and
the separating hyperplane defined by the SVM model.
Despite the different meanings of these scores, they all
roughly approximate increasing functions of predicted
binding strength, therefore the areas under the ROC
curves can be used as an objective measure of prediction
performance.
Predictions were made for each peptide sequence using
the corresponding SVRMHC model, the corresponding
additive model, as well as the four online predicting tools
SYFPEITHI, BIMAS, RANKPEP and SVMHC, and the
scores were used to make the ROC plots (Figure 2). The
SVRMHC models for the H2-Kb and H2-Db molecules
rendered AROC of 0.738 and 0.834, respectively, higher
than the AROC of any of the other predicting methods,
indicating that, in this test, the SVRMHC models per-
formed best compared to the other four prediction meth-
ods in identifying strong binding peptides for the mouse
class I MHC molecules.
Table 2: Comparison between the additive method and the SVRMHC method in models constructed with the H2-Db, H2-Kb and H2-
Kk datasets.
H2-Db H2-Kb H2-Kk
Additive Method SVRMHC Method Additive Method SVRMHC Method Additive Method SVRMHC Method
Numbers of outliers 6 3 7 6 2 0
r2 (self-consistency, 
outliers removed)
0.946 0.983 0.989 0.97 0.933 0.973
r2 (self-consistency, 
entire dataset)
0.602 0.749 0.37 0.568 0.849 0.973
Average Residual 
(entire dataset)
0.403 0.17 0.443 0.382 0.178 0.039
Average Residual 
(outliers removed)
0.187 0.043 0.095 0.13 0.151 0.039
q2 (LOO_CV) (outliers 
removed)
0.401 0.456 0.454 0.486 0.456 0.721Page 5 of 13
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Accurately predicting the binding between short peptides
and MHC molecules remains a major task for immunoin-
formatics. Quantitative prediction of exact peptide bind-
ing affinity represents the most recent development in the
field. Quantitative prediction is a finer-scale description of
binding, and the ability to construct effective quantitative
models manifests an improved understanding of the
mechanism of MHC-peptide interactions. There have
been two reported approaches to quantitative prediction
of MHC-peptide binding. The first approach makes use of
3D QSAR (quantitative structure-activity relationship)
techniques, and models the interaction between the pep-
tide and the MHC molecule using CosMSIA (Comparative
Molecular Similarity Indices Analysis) [33,34]. This
approach, though accurate, requires structural knowledge
about how the peptide and the MHC molecule interact
with each other in 3D space. The second approach to
quantitative modeling is the bioinformatics approach,
including the additive method and the SVRMHC method
presented here. In contrast to 3D-QSAR, this approach
uses only peptide sequences as their input, and does not
require any 3D structural information. This property
makes the bioinformatics methods more straightforward
and generally applicable. Particularly, they are more suit-
able for modeling the binding of less studied MHC mole-
cules for which no 3D structural information is available.
Linear models, as exemplified here by the additive
method, has previously demonstrated impressive per-
formance in modeling a variety of MHC-peptide binding
systems: the human class I allele HLA-A*0201 [14], the
mouse Class I MHC alleles [17] and the human class II
allele DRB1*0401 [15,16]. However, as is generally
known, properly chosen non-linear models can often out-
perform linear models in describing complex systems,
although linear models can often be more intuitive and
easily understood. Also, in many immunoinformatic
techniques, including the additive method, amino acid
residues are encoded by their identities, and the physico-
chemical properties of the amino acids are ignored. In this
study, we have addressed both problems. The use of a
non-linear SVR technique leads to an enhancement in
predictivity. Meanwhile, the adoption of an 11-factor
encoding of amino acids renders the resultant models sen-
sitive to similarities in important physicochemical proper-
ties among the residues in the peptides being modeled.
Support vector machines (SVMs) are a new class of learn-
ing machines motivated by statistical learning theory [35],
and they are gaining popularity because of their theoreti-
cally attractive features and profound empirical perform-
ance. Several reports have been seen in the literature
where SVM classification models were developed to ana-
lyze peptide binding profiles qualitatively [12,13,36]; yet,
to our knowledge, the current report is the first reported
quantitative modeling study in which the SVR technique
has been applied to model peptide binding.
In this study, we constructed SVRMHC models using the
binding data of three mouse class I alleles (H2-Db, H2-Kb
and H2-Kk), and compared the resulting models to a lin-
ear models, built using the additive method, constructed
using the same datasets. The models constructed with
SVRMHC have been shown to be superior to those con-
structed with linear methods, in terms of descriptive
power (as shown by a smaller number of "outliers"), pre-
diction accuracy (manifest as a higher cross-validated cor-
relation coefficient q2), self-consistency (higher non-
cross-validated explained variance r2), and overall preci-
sion in prediction (lower average residual of the predic-
tion). Although an improved performance was seen in all
three SVRMHC models, the levels of improvement dif-
fered between the models constructed for the three MHC
alleles. There seems to be a positive correlation between
Comparison of the six predicting methods – SVRMHC, addi-tive, SYFPEITHI, BIMAS, RANKPEP and SVMHC by ROC analysis (f r H2-Db and H2-Dk)Figure 2
Comparison of the six predicting methods – SVRMHC, addi-
tive, SYFPEITHI, BIMAS, RANKPEP and SVMHC by ROC 
analysis (for H2-Db and H2-Dk). The ROC curves of differ-
ent predicting methods are plotted in different colors. AROC 
(area underneath the ROC curve) is provided following the 
label of each predicting method.
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models and dataset size. With the largest of the three data-
sets – the H2-Kk dataset (154 peptides), the SVRMHC
method demonstrated the greatest level of improvement.
The LOO cross-validated q2 increased from 0.456 to
0.721. With the two smaller datasets – the H2-Db dataset
(65 peptides) and the H2-Dk dataset (62 peptides) – the
LOO cross-validated q2 increased from 0.401 and 0.454
for the additive models to 0.456 and 0.486 for the
SVRMHC models, respectively, marking a smaller
improvement than for H2-Kk. When we looked at the self-
consistency measure, with the two larger datasets (H2-Kk
and H2-Db), the SVRMHC models consistently demon-
strated higher levels of self-consistency than the linear
models for the entire datasets as well as for the datasets
after removal of outliers. For the smallest dataset, H2-Dk,
although the SVRMHC model produced a higher r2 than
the corresponding linear model for the entire dataset
(0.568 vs. 0.370); after outliers were removed, the
SVRMHC model produced a lower r2 than the additive
model did (0.970 vs. 0.989). The same trend is true for the
AR measurement. For the two larger datasets (H2-Kk and
H2-Db), the SVRMHC models consistently produced
lower AR values than the additive models for both the
entire datasets and for the datasets after removal of out-
liers. However, for the smallest dataset (H2-Dk), the
SVRMHC model produced a lower AR than the additive
model for the entire dataset (0.382 vs. 0.443), but a higher
AR than the additive model after the removal of outliers
(0.130 vs. 0.095). These observations suggest that the
SVRMHC approach may become more accurate as data-
sets grow.
In constructing the SVRMHC models, we applied the
same step-wise outlier determination and exclusion
scheme as used in [34] to ease the comparison between
the SVRMHC and the additive methods. There are disa-
greements in the outliers determined by the two methods
following the same step-wise outlier determining proce-
dure (Table 4): 4 out of the 6 "outliers" determined by
SVRMHC were also identified as "outliers" by the additive
method for H2-Kb; only 1 out of the 3 "outliers" deter-
mined by SVRMHC was classified as an "outlier" by the
additive method for H2-Db. These disagreements suggest
that this outlier detection procedure may not be most
accurate in identifying "true outliers" that reflect experi-
mental errors. However, the main focus of this study is to
demonstrate the performance of the SVRMHC method in
comparison with other methods, therefore, it is justifiable
to follow the same data pre-processing procedure as for
the additive method for the sake of performance compar-
ison. It is worth noting that after the model construction,
the performance of the models was also examined on the
whole dataset with the "outliers" added back, and
SVRMHC consistently demonstrated higher accuracy than
the linear method in the models constructed for all three
alleles (see Average Residual (entire dataset), Table 2).
Table 3: The scores used in the 11-factor encoding for the 20 amino acids, after scaling to the range [0, 1].
Amino 
Acid
Steric 
parameter
Hydrogen 
bond 
donors
Hydropho-
bicity scale
Hydrophi-
licity scale
Average 
accessible 
surface 
area
van der 
Waals 
parameter 
R0
van der 
Waals 
parameter 
epsilon
Free 
energy of 
solution 
in water
Average 
side chain 
orientation 
angle
Polarity Isoelectric 
point
A 0.510 0.169 0.471 0.279 0.141 0.294 0.000 0.262 0.512 0.000 0.404
R 0.667 0.726 0.321 1.000 0.905 0.529 0.327 0.169 0.372 1.000 1.000
N 0.745 0.390 0.164 0.658 0.510 0.235 0.140 0.313 0.116 0.065 0.330
D 0.745 0.304 0.021 0.793 0.515 0.235 0.140 0.601 0.140 0.956 0.000
C 0.608 0.314 0.760 0.072 0.000 0.559 0.140 0.947 0.907 0.028 0.285
Q 0.667 0.531 0.178 0.649 0.608 0.529 0.140 0.416 0.023 0.068 0.360
E 0.667 0.482 0.092 0.883 0.602 0.529 0.140 0.561 0.163 0.960 0.056
G 0.000 0.000 0.275 0.189 0.103 0.000 0.000 0.240 0.581 0.000 0.401
H 0.686 0.554 0.326 0.468 0.402 0.529 0.140 0.313 0.581 0.992 0.603
I 1.000 0.650 1.000 0.000 0.083 0.824 0.308 0.424 0.930 0.003 0.407
L 0.961 0.650 0.734 0.081 0.138 0.824 0.308 0.463 0.907 0.003 0.402
K 0.667 0.692 0.000 0.568 1.000 0.529 0.327 0.313 0.000 0.952 0.872
M 0.765 0.612 0.603 0.171 0.206 0.765 0.308 0.405 0.814 0.028 0.372
F 0.686 0.772 0.665 0.000 0.114 0.853 0.682 0.462 1.000 0.007 0.339
P 0.353 0.372 0.012 0.198 0.411 0.588 0.271 0.000 0.302 0.030 0.442
S 0.520 0.172 0.155 0.477 0.303 0.206 0.000 0.240 0.419 0.032 0.364
T 0.490 0.349 0.256 0.523 0.337 0.235 0.140 0.313 0.419 0.032 0.362
W 0.686 1.000 0.681 0.207 0.219 1.000 1.000 0.537 0.674 0.040 0.390
Y 0.686 0.796 0.591 0.477 0.454 0.853 0.682 1.000 0.419 0.031 0.362
V 0.745 0.487 0.859 0.036 0.094 0.647 0.234 0.369 0.674 0.003 0.399Page 7 of 13
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improvement of SVRMHC over the additive method is
primarily due to the SVR modeling technique, or it is pri-
marily attributed to the 11-factor encoding scheme for the
peptide sequences. We constructed SVR models with the
"sparse encoding" scheme following the same outlier
exclusion procedure as used in the additive models and
the SVRMHC models, and compared the three in their
performance. As shown in Table 5, the "SVR + sparse
encoding" method showed prediction performance that is
between those of the additive and the SVRMHC methods
for two of the three alleles – H2-Db and H2-Kk. For H2-
Db, "SVR + sparse encoding" achieved a similar LOO
cross-validated q2 (0.459) to that of SVRMHC (0.456), but
it excluded a larger number of outliers than SVRMHC (5
vs. 3). For H2-Kk, "SVR + sparse encoding" achieved a
LOO cross-validated q2 of 0.523, which is between the
LOO cross-validated q2 values of the additive (0.456) and
SVRMHC method (0.721); and it excluded 1 outlier, also
between the additive method (2 outliers excluded) and
SVRMHC (no outlier excluded). This seems to suggest that
both the SVR modeling technique and the 11-factor
encoding scheme contributed to the superior perform-
ance of SVRMHC. However, we were surprised to see that
the "SVR + sparse encoding" model for H2-Kb performed
worse than both the SVRMHC model and the additive
model (LOO cross-validated q2 = 0.352, with 8 outliers
removed), which is difficult to interpret. In order to be
conclusive on this issue, models for a larger number of
alleles need to be constructed and used in comparison;
and this we intend to do in the near future.
The ROC analysis allows us to compare of several predic-
tion tools for MHC-peptide binding: SVRMHC, the addi-
tive method, SYFPEITHI, BIMAS, RANKPEP and SVMHC.
Our ROC analysis indicated that the SVRMHC method,
with an average AROC of 0.786, was the most accurate in
identifying strong binders for the two mouse MHC mole-
cules H2-Db and H2-Kb. It is followed by SYFPEITHI and
the additive method (with average AROC = 0.727 and
0.726, respectively). SVMHC (average AROC = 0.704),
BIMAS (average AROC = 0.695) and RANKPEP (average
Table 4: The outliers determined by the additive method and the SVRMHC method for H2-Db, H2-Kb and H2-Kk. Common outliers 
determined by both methods are italicized.
H2-Db
Outliers determined by Additive method Outliers determined by SVRMHC method
True pIC50 Predicted pIC50 
(Additive)
Predicted pIC50 
(SVRMHC)
True pIC50 Predicted pIC50 
(Additive)
Predicted pIC50 
(SVRMHC)
QLPPNSLLI 3.53 6.19 7.06 QLPPNSLLI 3.53 6.19 7.06
GFKSNFNKI 3.36 6.30 5.28 TAGANPMDL 4.66 4.84 7.30
IKPSNSEDL 5.54 7.70 6.33 CKGVNKEYL 7.41 7.13 5.14
TALANTIEV 8.44 5.75 7.02
TGKLNLENL 4.75 7.10 6.47
AEDTNVSLI 3.36 5.73 4.62
H2-Kb
Outliers determined by Additive method Outliers determined by SVRMHC method
True pIC50 Predicted pIC50 
(Additive)
Predicted pIC50 
(SVRMHC)
True pIC50 Predicted pIC50 
(Additive)
Predicted pIC50 
(SVRMHC)
NTVVFDAL 3.81 6.97 7.44 NTVVFDAL 3.81 6.97 7.44
LQQRYSRL 9.22 5.80 6.42 LQQRYSRL 9.22 5.80 6.42
SKLQYKII 3.81 6.96 6.66 SKLQYKII 3.81 6.96 6.66
QPQNYLRL 4.29 9.49 6.61 QPQNYLRL 4.29 9.49 6.61
MGLIYNRM 8.34 6.21 7.56 VLLDYQGM 5.48 5.62 7.95
IIFLFILL 5.13 7.85 6.36 SIILFLPL 9.00 8.81 6.72
MWYWGPSL 5.13 7.58 7.11
H2-Kk
Outliers determined by Additive method Outliers determined by SVRMHC method
True pIC50 Predicted pIC50 
(Additive)
Predicted pIC50 
(SVRMHC)
(none)
FESTGNLE 4.71 6.56 4.39
FRSTGNLI 4.19 6.76 4.44Page 8 of 13
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methods we compared. We need to stress, though, that
this comparison is based on the models constructed for
only two MHC molecules, and this rank order may not be
true in the general case.
Questions may be raised about the fairness of the ROC-
based comparison, because there are overlaps between the
MHCBN data used in the ROC analysis and the data used
in model construction for all five methods we compared.
Ideally, a comparison based on a totally independent
dataset, one with no overlaps with the data used in the
model construction of any of the five methods, would be
desirable. However, without information about what pep-
tides were used in the model construction of the SYF-
PEITHI, BIMAS, RANKPEP and SVMHC methods, we
believe it likely that there are higher levels of overlaps
between the datasets used in model construction of the
three qualitative models than those used for the two
quantitative methods – additive and SVRMHC – because
qualitative data are much more abundant than quantita-
tive binding data. Nevertheless, we removed all peptides
in the test datasets that overlapped with the datasets used
in the construction of the additive and SVRMHC models
(15 peptides for H2-Db, and 11 peptides for H2-Kb) and
conducted a ROC-based comparison using the remaining
data (Table 6). This is a very "unfair" comparison, because
overlapped peptides for the additive and SVRMHC mod-
els were removed, but those for the other methods were
not. Yet, the results indicated that the SVRMHC model for
H2-Kb (AROC = 0.83) still out-performed the models for all
other methods; and the SVRMHC model for H2-Db,
though did not achieve as high AROC as BIMAS (0.66) or
RANKPEP (0.677), but was still close to them (0.658).
Despite their encouraging performance, SVR-based mod-
els reported here also exhibit some disadvantages. Most
notably, these models are "black box" models, and are
poorly interpretable. We cannot infer, for example, which
peptide positions are the most important in determining
the strength of the MHC-peptide binding. Not that this
necessarily obviates the utility of SVRMHC models as an
immunological tool.
Currently, we are working to improve further SVR-based
modeling methods, focusing on testing different combi-
nations of physicochemical properties in the feature
encoding scheme. We also plan to construct MHC-peptide
binding models for other MHC molecules hosted in the
AntiJen database [37,38] and to make these prediction
models available online. In the next phase of this project,
we will adapt the SVR-based methodology to the more
challenging task of predicting the MHC-peptide binding
of class II MHCs.
Conclusion
In this paper, we demonstrated SVRMHC, a SVR-based
quantitative modeling approach to model peptide-MHC
binding affinities, and showed that SVRMHC is a promis-
ing immunoinformatics tool with not inconsiderable
future potential. With the ongoing, rapid development of
high-throughput functional proteomics technologies,
such as peptide microarray technology, the SVR modeling
approach is expected to see broader use in modeling
MHC-peptide binding, and protein-peptide binding reac-
tions in general.
Methods
Support Vector Machine Regression (SVR) overview
Support Vector Machines (SVMs) are a class of learning
machines based on statistical learning theory [18,35].
Table 5: Comparison of performance between the additive method, SVRMHC, and SVR models with sparse encoding scheme for H2-
Db, H2-Kb and H2-Kk.
Additive method SVRMHC SVR, Sparse encoding
H2-Db Numbers of outliers 6 3 5
q2(LOO_CV) 0.401 0.456 0.459
H2-Kb Numbers of outliers 7 6 8
q2(LOO_CV) 0.454 0.486 0.352
H2-Kk Numbers of outliers 2 0 1
q2(LOO_CV) 0.456 0.721 0.523
Table 6: ROC-based comparison of the five predicting methods – SVRMHC, additive, SYFPEITHI, BIMAS, RANKPEP and SVMHC, 
after overlapped peptides were removed for SVRMHC and additive methods, but not for the four qualitative methods.
SVRMHC Additive BIMAS SYFPEITHI RANKPEP SVMHC
H2-Db 0.658 0.58 0.66 0.646 0.677 0.632
H2-Kb 0.83 0.766 0.769 0.731 0.485 0.748Page 9 of 13
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SVMs have been extended to solve nonlinear regression
estimation [35]. In SVR, with input data set
 (where xi is the input vector, di is the
desired real-valued labeling, and n is the number of the
input records), x is first mapped into a higher-dimension
feature space F via a nonlinear mappingΘ, then linear
regression is performed in this space. In other words, SVR
approximate a function using the following equation
y = f(x) = wΘ(x) + b  (2)
The coefficients wand b are estimated by minimizing
where Lε (d, y) is the empirical error measured by ε-insen-
sitive loss function
and the term 1/2||w||2 is a regularization term. The con-
stant C is specified by the user, and it determines the
trade-off between the empirical risk and the regularization
term. ε is also specified by the user, and it is equivalent to
the approximation accuracy of the training data.
The estimations of w and b are obtained by transforming
Eq. (3) into the primal function:
By introducing Lagrange multipliers, the optimization
problem can be transformed into a quadratic program-
ming problem. The solution takes the following form:
where K is the kernel function K(x, xi) = Θ(x)T Θ(xi) By
using of a kernel function, we can deal with problems of
arbitrary dimensionality without having to compute the
mapping Θ explicitly. Commonly used kernels include
the linear kernel, polynomial kernel, and the radial basis
function (RBF) kernel. In this exploration, we chose to use
the RBF (radial basis function) kernel as recommended in
Chang and Lin [39]. The RBF kernel takes the following
form:
K(xi, xi) = exp(-γ||x - xi||2), γ > 0.  (7)
Data description
We constructed SVRMHC models using three MHC-pep-
tide binding datasets for mouse Class I MHC alleles. These
sets have been used previously to construct models using
the additive method [17], facilitating comparison
between the two methods. The data consists of peptide
sequences and experimentally measured binding affinities
(expressed numerically as pIC50). The first dataset con-
tains 65 nonamer peptides (H2-Db allele), the second
dataset 62 octamers (H2-Kb), and the third dataset 154
octamer peptides (H2-Kk).
Encoding scheme of peptide sequences
The most widely-used representation of an amino acid
sequence in immunoinformatic modelling is the "sparse
encoding" scheme [12,40]. However, such an encoding
scheme does not account for any similarity in physico-
chemical properties between amino acids. We developed
a new encoding method. First, from AA-index [41], we
picked a list of what we considered as important general
physicochemical properties (e.g., polarity, isoelectric
point, and accessible surface area). Into this list, we added
a number of properties that were identified in 3-D QSAR
analysis [34] as key determinants of peptide-MHC interac-
tion (volume, number of hydrogen bond donors, hydro-
phobicity). This led to a list of properties that consists of
17 physicochemical indices. We calculated the pair-wise
correlation coefficients (r2) of these 17 factors. For any
pair of factors with r2 > 0.8, we eliminated one of the two
factors. In the end, a list of 11 factors was obtained. The
values of the 11 physicochemical parameters were linearly
scaled to the range [0, 1] for the 22 amino acids (Table 5).
The list of the 17 factors and their pair-wise r2 are pre-
sented in online supplementary material [19]. As input to
the SVRMHC models, a given octamer or nonamer pep-
tide sequence is represented as a long vector concatenated
from the eight or nine numerical vectors (each of length
11) encoding the corresponding residue in the sequence.
We name this encoding scheme the "11-factor encoding".
Outlier determination and exclusion
To ease comparison of SVRMHC models and those con-
structed previously using the additive method, we applied
the same step-wise outlier determination and exclusion
scheme as used in [34]. For each dataset, a SVRMHC
model was first constructed using the whole dataset, and
prediction was made for each sequence in the whole data-
set. We called this model the "self-testing model". If at
least one sequence in the dataset produced a residual
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ual value is defined as the absolute value of the difference
between the predicted affinity and true affinity on loga-
rithm scale), then the sequence with the maximum resid-
ual value was excluded as an outlier, and a replacement
self-testing model was constructed using the remaining
sequences. This procedure was repeated until all
sequences in the dataset had residual values < 2.0 log
units.
Assessment of model performance
The performance of the SVRMHC models was assessed
using several metrics. The number of outliers determined
and excluded can be considered as a measurement of
"descriptive power" of a model: a model that excludes a
smaller number of outliers is better at describing the data-
set as a whole than a model that excludes a greater
number of outliers. For the final self-testing model (the
self-testing model after all outliers are removed), we can
assess its "self-consistency" using the explained variance
(or squared correlation coefficient) r2 (see [17]).
The most important measure of a model's performance is
its prediction accuracy, which can be assessed by the cross-
validated correlation coefficient, q2, of the model:
where n is the number of peptides in the dataset, pIC50i
and  are the predicted and experimentally meas-
ured pIC50 values for the ith peptide, respectively, and
 is the mean of the experimentally measured
pIC50 values. As in [17], we used leave-one-out (LOO)
cross-validation to check our models' prediction perform-
ance.
Another metric that can be used to assess the performance
of the models is the average residual (AR), defined simply
as
The AR is a measure of the overall precision of the predic-
tion made by the model. A model with a lower AR overall
makes more precise prediction than a model with a higher
AR.
ROC analysis and comparisons of SVR models with other 
predicting tools
Prediction performance of any classification-type model
can be assessed by the combination of two parameters:
"false positive rate" and the "false negative rate" or, equiv-
alently, specificity and sensitivity. Sensitivity is defined as 1-
"false negative rate", and specificity is defined as the 1-
"false positive rate". A plot of sensitivity vs. (1-specificity) is
known as the ROC curve.
In the MHC ligand database MHCBN [32], all nomamer
ligands for the H2-Db molecule and all octamer ligands
for H2-Kb and H2-Kk were downloaded. In the MHCBN
database, the peptide ligands are classified into five cate-
gories: "high binding", "moderate binding", "low bind-
ing", "no-binding" and "unknown". We grouped all
peptides in the "high binding" and "moderate binding"
categories together as "strong binders", all peptides in the
"low binding" and "no-binding" categories together as
"weak binders", and discarded the peptides in the
"unknown" category. All ligands for the H2-Kk molecule
downloaded from MHCBN were "strong binders", there-
fore the ROC analysis was not performed with H2-Kk.
The scores used for the SVRMHC method in the ROC
analysis were the predicted pIC50 values of the test ligands
for the final SVRMHC models. The scores used for the
additive method [42], SYFPEITHI [43], BIMAS [44],
RANKPEP [45], and SVMHC [46] were obtained by query-
ing the corresponding online predicting servers. Default
parameters were used when making the queries. After the
scores of all peptides for a MHC molecule (H2-Db or H2-
Kb) were obtained, each score value was used in turn as a
cut-off point. At each cut-off point , the true positive rate
was calculated as
where si is the predicted score for peptide i, and S is the set
of all "strong binders". The false positive rate was calcu-
lated as
where W is the set of all "weak binders". The ROC curve
was plotted as rf,p vs. rt,p.
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